The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up

- NACT use among SGO members for ovarian cancer is explored given recent trials.
- Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.
- Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.
- Very high optimal cytoreduction rates are reported from SGO members.
- Despite recent studies, SGO members don't regularly treat patients with NACT/ID.